Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

Novo (up 1-7/8 to 24-7/8) and Alza (up 1-1/4 to 20-3/8) were the only strong performers among pharmaceutical/health care stocks as issues on the "F-D-C" Index retreated broadly the week ended Nov. 16. Only seven of the 53 stocks finished the week ahead, while 40 lost ground and six remained unchanged. Among the five stocks moving ahead fractionally, Payless, which reported a 22% jump in third quarter net income, to $4.6 mil., on a 9.5% volume gain, to $223.5 mil., added 3/4 to 22-3/4. SmithKline edged up 5/8 to 52-5/8. The Diversifieds suffered the largest losses, with Sterling and Revlon each losing 2-1/2, to 26-7/8 and 33-1/2, respectively. Forest slid 1-7/8 to 13. Among the Pharmaceuticals, Key fell one point to 9-3/4. Key was on the AMEX most active list on Monday, Nov. 12 and Tuesday, Nov. 13, when the stock hit a 1984 low at 9. In Value Line's quarterly rundown on the pharmaceutical industry, which came out on Nov. 16, only Bristol-Myers, Lilly, Marion, and Pfizer were given an above average rating for anticipated relative performance over the next 12 months. Chart omitted.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts